Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belatacept - Bristol-Myers Squibb

Drug Profile

Belatacept - Bristol-Myers Squibb

Alternative Names: BMS-224818; CTLA4-IgLEA29Y; LEA 29Y; Nulojix

Latest Information Update: 12 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Emory University; National Heart, Lung and Blood Institute
  • Class Drug conjugates; Immunoconjugates; Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action CD80 antigen inhibitors; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection
  • Phase II Lung transplant rejection
  • Discontinued Liver transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 28 Oct 2019 Phase-II clinical trials in Lung transplant rejection (Combination therapy, Prevention) in USA (IV) (NCT03388008)
  • 02 May 2019 Duke University and Bristol-Myers Squibb withdraws a phase II trial for Lung transplant rejection in the USA, prior to enrolment (NCT03805178)
  • 13 Feb 2019 Belatacept is still in phase III trial for Renal transplant rejection (Prevention, Treatment-experienced, In adults, In the elderly) in Argentina, Colombia and Norway (NCT01820572)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top